Effects of atorvastatin on systemic and renal nitric oxide in healthy man

Clinical and Experimental Hypertension

Volumn 35, Issue 2, 2013, Pages 148-157

  Mose, Frank Holden ^a,b   Larsen, Thomas ^a,b   Bech, Jesper Noergaard ^a,b   Pedersen, Erling Bjerregaard ^a,b  

^a HOLSTEBRO HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

Blood pressure; Fractional excretion of sodium; Nitric oxide; Renin angiotensin system; Statin

Indexed keywords

ATORVASTATIN; N(G) METHYLARGININE; NITRIC OXIDE; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; MALE; NORMAL HUMAN; PLEIOTROPY; RANDOMIZED CONTROLLED TRIAL; SODIUM EXCRETION; URINE VOLUME;

ADOLESCENT; ADULT; AQUAPORIN 2; ARGININE; BLOOD FLOW VELOCITY; BLOOD PRESSURE; CROSS-OVER STUDIES; FEMALE; GLOMERULAR FILTRATION RATE; HEART RATE; HEPTANOIC ACIDS; HORMONES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; MALE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PLACEBOS; POTASSIUM; PULSATILE FLOW; PYRROLES; RENIN-ANGIOTENSIN SYSTEM; SODIUM CHLORIDE; VASCULAR STIFFNESS; YOUNG ADULT;

EID: 84875719877     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.3109/10641963.2012.702835     Document Type: Article

References (45)

1. Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 2001; 292(5519): 1160-1164. (Pubitemid 32440937)
2. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360(9326):7-22. (Pubitemid 34756487)
3. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376(9753):1670-1681.
4. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009; 338:b2376.
5. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335(14):1001-1009. (Pubitemid 26338729)
6. Pedersen TR, Kjekshus J, Berg K, et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. Atheroscler Suppl 2004; 5(3):81-87.
7. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350(15):1495-1504. (Pubitemid 38477774)
8. Wang CY, Liu PY, Liao JK. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med 2008; 14(1):37-44.
9. Liao JK. Clinical implications for statin pleiotropy. Curr Opin Lipidol 2005; 16(6):624-629. (Pubitemid 43012159)
10. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004; 57(7):728-734. (Pubitemid 38901488)
11. Tonelli M, Moye L, Sacks FM, Cole T, Curhan GC. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 2003; 14(6):1605-1613. (Pubitemid 36687063)
12. Lecian D, Demova H, Lodererova A, et al. Renal effects of HMG-CoA reductase inhibition in a rat model of chronic inhibition of nitric oxide synthesis. Kidney Blood Press Res 2006; 29(3):135-143. (Pubitemid 44597752)
13. Atthobari J, Brantsma AH, Gansevoort RT, et al. The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study. Nephrol Dial Transplant 2006; 21(11):3106-3114. (Pubitemid 44567081)
14. Paulsen L, Holm C, Bech JN, Starklint J, Pedersen EB. Effects of statins on renal sodium and water handling: acute and short-term effects of atorvastatin on renal haemodynamics, tubular function, vasoactive hormones, blood pressure and pulse rate in healthy, normocholesterolemic humans. Nephrol Dial Transplant 2008; 23(5):1556-1561.
15. Christensen FH, Hansen T, Stankevicius E, Buus NH, Simonsen U. Elevated pressure selectively blunts flow-evoked vasodilatation in rat mesenteric small arteries. Br J Pharmacol 2007; 150(1):80-87. (Pubitemid 46094672)
16. Kurtz A, Wagner C. Role of nitric oxide in the control of renin secretion. Am J Physiol 1998; 275(6 Pt 2):F849-F862.
17. Ortiz PA, Garvin JL. Role of nitric oxide in the regulation of nephron transport. Am J Physiol Renal Physiol 2002; 282(5): F777-F784. (Pubitemid 34654482)
18. Bech JN, Nielsen CB, Pedersen EB. Effects of systemic NO synthesis inhibition on RPF, GFR, UNa, and vasoactive hormones in healthy humans. Am J Physiol 1996; 270(5 Pt 2): F845-F851.
19. Larsen T, Mose FH, Bech JN, Pedersen EB. Effect of nitric oxide inhibition on blood pressure and renal sodium handling. A dose-response study in healthy man. Clin Exp Hypertens 2012. doi:10.3109/10641963.2012.681727
20. John S, Delles C, Jacobi J, et al. Rapid improvement of nitric oxide bioavailability after lipid-lowering therapy with cerivastatin within two weeks. J Am Coll Cardiol 2001; 37(5):1351-1358.
21. Ott C, Schlaich MP, Schmidt BM, Titze SI, Schaufele T, Schmieder RE. Rosuvastatin improves basal nitric oxide activity of the renal vasculature in patients with hypercholesterolemia. Atherosclerosis 2008; 196(2):704-711.
22. Omori H, Nagashima H, Tsurumi Y, et al. Direct in vivo evidence of a vascular statin: a single dose of cerivastatin rapidly increases vascular endothelial responsiveness in healthy normocholesterolaemic subjects. Br J Clin Pharmacol 2002; 54(4):395-399. (Pubitemid 35334952)
23. John S, Schneider MP, Delles C, Jacobi J, Schmieder RE. Lipidindependent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients. Am Heart J 2005; 149(3):473.
24. Landmesser U, Bahlmann F, Mueller M, et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005; 111(18):2356-2363. (Pubitemid 40647072)
25. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMGcoenzyme a reductase inhibitor, improves endothelial function within 1 month. Circulation 1997; 95(5):1126-1131. (Pubitemid 27097821)
26. Chen H, Ren JY, Xing Y, et al. Short-term withdrawal of simvastatin induces endothelial dysfunction in patients with coronary artery disease: a dose-response effect dependent on endothelial nitric oxide synthase. Int J Cardiol 2009; 131(3): 313-320.
27. Ludolph B, Bloch W, Kelm M, Schulz R, Kleinbongard P. Shortterm effect of the HMG-CoA reductase inhibitor rosuvastatin on erythrocyte nitric oxide synthase activity. Vasc Health Risk Manag 2007; 3(6):1069-1073.
28. Energy and protein requirements. Report of a joint FAO/WHO/UNU Expert Consultation. World Health Organ Tech Rep Ser 1985; 724:1-206.
29. Matthesen SK, Larsen T, Vase H, Lauridsen TG, Pedersen EB. Effect of potassium supplementation on renal tubular function, ambulatory blood pressure and pulse wave velocity in healthy humans. Scand J Clin Lab Invest 2011; 72(1):78-86.
30. Pedersen RS, Bentzen H, Bech JN, Pedersen EB. Effect of water deprivation and hypertonic saline infusion on urinary AQP2 excretion in healthy humans. Am J Physiol Renal Physiol 2001; 280(5):F860-F867.
31. Hager H, Kwon TH, Vinnikova AK, et al. Immunocytochemical and immunoelectron microscopic localization of alpha-, beta-, and gamma-ENaC in rat kidney. Am J Physiol Renal Physiol 2001; 280(6):F1093-F1106.
32. Melikian N, Seddon MD, Casadei B, Chowienczyk PJ, Shah AM. Neuronal nitric oxide synthase and human vascular regulation. Trends Cardiovasc Med 2009; 19(8):256-262.
33. Mount PF, Power DA. Nitric oxide in the kidney: functions and regulation of synthesis. Acta Physiol (Oxf) 2006; 187(4):433-446.
34. Antoniades C, Bakogiannis C, Leeson P, et al. Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterinmediated endothelial nitric oxide synthase coupling. Circulation 2011; 124(3):335-345.
35. Datar R, Kaesemeyer WH, Chandra S, Fulton DJ, Caldwell RW. Acute activation of eNOS by statins involves scavenger receptor-B1, G protein subunit Gi, phospholipase C and calcium influx. Br J Pharmacol 2010; 160(7): 1765-1772.
36. Mattson DL. Importance of the renal medullary circulation in the control of sodium excretion and blood pressure. Am J Physiol Regul Integr Comp Physiol 2003; 284(1): R13-R27. (Pubitemid 36008650)
37. Lockhart JC, Larson TS, Knox FG. Perfusion pressure and volume status determine the microvascular response of the rat kidney to NG-monomethyl-L- arginine. Circ Res 1994; 75(5):829-835.
38. Damkjaer M, Vafaee M, Moller ML, et al. Renal cortical and medullary blood flow responses to altered NO availability in humans. Am J Physiol Regul Integr Comp Physiol 2010; 299(6): R1449-R1455.
39. Bech JN, Nielsen EH, Pedersen RS, Svendsen KB, Pedersen EB. Enhanced sodium retention after acute nitric oxide blockade in mildly sodium loaded patients with essential hypertension. Am J Hypertens 2007; 20(3):287-295. (Pubitemid 46283360)
40. Ott C, Ritt M, Titze SI, Schaufele T, Schmieder RE. Rosuvastatin does not affect intrarenal hemodynamics in patients with hypercholesterolemia. J Nephrol 2009; 22 (5):675-681.
41. Lauridsen TG, Vase H, Starklint J, et al. Increased renal sodium absorption by inhibition of prostaglandin synthesis during fasting in healthy man. A possible role of the epithelial sodium channels. BMC Nephrol 2010; 11:28.
42. Garvin JL, Ortiz PA. The role of reactive oxygen species in the regulation of tubular function. Acta Physiol Scand 2003; 179(3):225-232. (Pubitemid 37474083)
43. Wassmann S, Laufs U, Muller K, et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 2002; 22(2):300-305. (Pubitemid 34127043)
44. Wagner AH, Kohler T, Ruckschloss U, Just I, Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMGCoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 2000; 20(1):61-69. (Pubitemid 30048347)
45. Briones AM, Rodriguez-Criado N, Hernanz R, et al. Atorvastatin prevents angiotensin II-induced vascular remodeling and oxidative stress. Hypertension 2009; 54(1): 142-149.